Incretin-based Drugs Market Share ,Outlook, Competitive Strategies and Segment Forecast to 2034
Global Incretin-based Drugs Market Size – By Drug Type, By Route of Administration, By Indication, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Aug-2025 | Report ID: HLCA25259 | Pages: 1 - 244 | Formats*: |
| Category : Healthcare | |||
Incretin-based Drugs Market Introduction and Overview –
According to SPER Market Research, the Global Incretin-based Drugs Market is estimated to reach USD 71.11 billion by 2034 with a CAGR of 6.52%.
The report includes an in-depth analysis of the Global Incretin-based Drugs Market, including market size and trends, product mix, Applications, and supplier analysis. The Global Incretin-based Drugs market was valued at USD 37.81 billion in 2024 and is projected to increase at a compound annual growth rate (CAGR) of 6.52% between 2025 and 2034. Incretin-based therapies are a category of drugs prescribed to treat type 2 diabetes. They function by enhancing the action of gut hormones known as incretins. These hormones prompt the pancreas to secrete insulin when food is consumed, helping to regulate and reduce blood sugar levels in the body. This mechanism assists individuals with type 2 diabetes in achieving better glycemic control.
By Drugs Type Insights
The incretin-based drugs market is segmented into GLP-1 receptor agonists and DPP-4 inhibitors. Among these, GLP-1 receptor agonists are witnessing significant growth due to the increasing cases of type 2 diabetes worldwide. Most individuals diagnosed with diabetes are affected by type 2, highlighting the demand for effective treatment options. These drugs help regulate blood sugar by boosting insulin secretion and lowering glucagon levels after meals. Research also shows that medications like Semaglutide improve glucose control. Additionally, they aid in weight loss by reducing hunger and slowing digestion. The development of weekly injection options further enhances patient convenience and adherence.
By Route of Administration Insights
The incretin-based drugs market is divided by route of administration into oral and injectable forms. Among these, oral drugs are gaining traction due to their ease of use and better patient acceptance compared to injections. Many diabetes patients show a clear preference for oral treatments over injectable ones. Continuous advancements in oral drug formulations have improved their effectiveness and safety, encouraging better adherence. For example, new developments like nonpeptide oral GLP-1 receptor agonists are being explored for managing weight and diabetes. Oral drugs are also easier to store, transport, and administer, reducing pressure on healthcare systems and enhancing patient convenience.
Regional Insights
North America holds a significant share in the incretin-based drugs market, with the U.S. leading due to its high burden of chronic illnesses like type 2 diabetes, obesity, and heart-related conditions. These health concerns are driving the demand for effective treatment options. The U.S. has a large diabetic population, most of whom are affected by type 2 diabetes, making blood sugar control and weight management crucial. Factors such as increasing obesity rates, lack of physical activity, and an aging population further fuel the rise in diabetes. As a result, incretin-based drugs are becoming increasingly important in disease management across the region.
Market Competitive Landscape
Key companies like AstraZeneca, Eli Lilly, Novo Nordisk, and Pfizer dominate the incretin-based drugs market. Their growth is driven by innovation, partnerships, and public health awareness. Collaborations and social media campaigns boost treatment adoption, helping firms strengthen their position in the expanding chronic disease treatment space. Some key players are- AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Lupin, Merck, Novo Nordisk, Pfizer, Sanofi, Takeda, and Viatris.
Recent Developments:
In March 2024, Eli Lilly partnered with Amazon Pharmacy to offer home delivery of medicines for diabetes, obesity, and migraine, including its GLP-1 weight-loss drug Zepbound. This partnership expanded Eli Lilly’s reach and improved access to treatment, supporting better health outcomes.
In November 2023, AstraZeneca entered an exclusive licensing agreement with Eccogene for ECC5004, a once-daily oral GLP-1 receptor agonist aimed at treating type 2 diabetes, obesity, and other cardiometabolic disorders. This collaboration enhanced AstraZeneca’s chronic care product line and strengthened its future position in the growing market for diabetes and obesity treatments.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Drug Type, By Route of Administration, By Indication, By Distribution Channel |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Lupin, Merck, Novo Nordisk, Pfizer, Sanofi, Takeda, Viatris. |
Key Topics Covered in the Report
- Global Incretin-based Drugs Market Size (FY’2021-FY’2034)
- Overview of Global Incretin-based Drugs Market
- Segmentation of Global Incretin-based Drugs Market By Drugs Type (GLP-1 receptor agonists, DPP-4 inhibitors)
- Segmentation of Global Incretin-based Drugs Market By Route of Administration (Oral, Injectable)
- Segmentation of Global Incretin-based Drugs Market By Indication (Type 2 diabetes mellitus, Obesity and weight management, Other metabolic disorders)
- Segmentation of Global Incretin-based Drugs Market By Distribution Channel (Hospital pharmacies, Retail pharmacies, E-commerce)
- Statistical Snap of Global Incretin-based Drugs Market
- Expansion Analysis of Global Incretin-based Drugs Market
- Problems and Obstacles in Global Incretin-based Drugs Market
- Competitive Landscape in the Global Incretin-based Drugs Market
- Details on Current Investment in Global Incretin-based Drugs Market
- Competitive Analysis of Global Incretin-based Drugs Market
- Prominent Players in the Global Incretin-based Drugs Market
- SWOT Analysis of Global Incretin-based Drugs Market
- Global Incretin-based Drugs Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1.Introduction
1.1.Scope of the report1.2.Market segment analysis
2.Research Methodology
2.1.Research data source2.1.1.Secondary Data2.1.2.Primary Data2.1.3.SPERs internal database2.1.4.Premium insight from KOLs2.2.Market size estimation2.2.1.Top-down and Bottom-up approach2.3.Data triangulation
3.Executive Summary
4.Market Dynamics
4.1.Driver, Restraint, Opportunity and Challenges analysis
4.1.1.Drivers4.1.2.Restraints4.1.3.Opportunities4.1.4.Challenges
5.Market variable and outlook
5.1.SWOT Analysis5.1.1.Strengths5.1.2.Weaknesses5.1.3.Opportunities5.1.4.Threats5.2.PESTEL Analysis5.2.1.Political Landscape5.2.2.Economic Landscape5.2.3.Social Landscape5.2.4.Technological Landscape5.2.5.Environmental Landscape5.2.6.Legal Landscape5.3.PORTERs Five Forces5.3.1.Bargaining power of suppliers5.3.2.Bargaining power of buyers5.3.3.Threat of Substitute5.3.4.Threat of new entrant5.3.5.Competitive rivalry5.4.Heat Map Analysis
6.Competitive Landscape
6.1.Global Incretin-based Drugs Market Manufacturing Base Distribution, Sales Area, Product Type6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Incretin-based Drugs Market
7.Global Incretin-based Drugs Market, By Drugs Type (USD Million) 2021-2034
7.1.GLP-1 receptor agonists7.2.DPP-4 inhibitors
8.Global Incretin-based Drugs Market, By Route of Administration (USD Million) 2021-2034
8.1.Oral8.2.Injectable
9.Global Incretin-based Drugs Market, By Indication (USD Million) 2021-2034
9.1.Type 2 diabetes mellitus9.2.Obesity and weight management9.3.Other metabolic disorders
10.Global Incretin-based Drugs Market, By Distribution Channel (USD Million) 2021-2034
10.1.Hospital pharmacies10.2.Retail pharmacies10.3.E-commerce
11.Global Incretin-based Drugs Market, (USD Million) 2021-2034
11.1.Global Incretin-based Drugs Market Size and Market Share
12.Global Incretin-based Drugs Market, By Region, (USD Million) 2021-2034
12.1.Asia-Pacific12.1.1.Australia12.1.2.China12.1.3.India12.1.4.Japan12.1.5.South Korea12.1.6.Rest of Asia-Pacific12.2.Europe12.2.1.France12.2.2.Germany12.2.3.Italy12.2.4.Spain12.2.5.United Kingdom12.2.6.Rest of Europe12.3.Middle East and Africa12.3.1.Kingdom of Saudi Arabia12.3.2.United Arab Emirates12.3.3.Qatar12.3.4.South Africa12.3.5.Egypt12.3.6.Morocco12.3.7.Nigeria12.3.8.Rest of Middle-East and Africa12.4.North America12.4.1.Canada12.4.2.Mexico12.4.3.United States12.5.Latin America12.5.1.Argentina12.5.2.Brazil12.5.3.Rest of Latin America
13.Company Profile
13.1.AstraZeneca13.1.1.Company details13.1.2.Financial outlook13.1.3.Product summary13.1.4.Recent developments13.2.Boehringer Ingelheim13.2.1.Company details13.2.2.Financial outlook13.2.3.Product summary13.2.4.Recent developments13.3.Eli Lilly and Company13.3.1.Company details13.3.2.Financial outlook13.3.3.Product summary13.3.4.Recent developments13.4.GlaxoSmithKline13.4.1.Company details13.4.2.Financial outlook13.4.3.Product summary13.4.4.Recent developments13.5.Lupin Limited13.5.1.Company details13.5.2.Financial outlook13.5.3.Product summary13.5.4.Recent developments13.6.Merck13.6.1.Company details13.6.2.Financial outlook13.6.3.Product summary13.6.4.Recent developments13.7.Novo Nordisk13.7.1.Company details13.7.2.Financial outlook13.7.3.Product summary13.7.4.Recent developments13.8.Pfizer13.8.1.Company details13.8.2.Financial outlook13.8.3.Product summary13.8.4.Recent developments13.9.Sanofi13.9.1.Company details13.9.2.Financial outlook13.9.3.Product summary13.9.4.Recent developments13.10.Takeda Pharmaceutical Company13.10.1.Company details13.10.2.Financial outlook13.10.3.Product summary13.10.4.Recent developments13.11.Others
14.Conclusion
15.List of Abbreviations
16.Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Incretin-based Drugs Market is projected to reach USD 71.11 by 2034, growing at a CAGR of 6.52 % during the forecast period.
Incretin-based Drugs Market size from 2025. The Market is expected to reach USD 71.11 by 2034, at a CAGR of 6.52% during the forecast period.
Incretin-based Drugs Market CAGR of 6.52% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Incretin-based Drugs Market size is USD 71.11 from 2025 to 2034.
Incretin-based Drugs Market covered By Drug Type, By Route of Administration, By Indication, By Distribution Channel
The North America is anticipated to have the highest Market share in the Incretin-based Drugs Market .
"
AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Lupin, Merck, Novo Nordisk, Pfizer, Sanofi, Takeda, Viatris."
The report includes an in-depth analysis of the Global Incretin-based Drugs Market, including market size and trends, product mix, Applications, and supplier analysis
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
